Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

Kratom at a crossroads: Trends, controversies, and the evidence gap

AI Summary
  • Rising kratom use in the United States means physicians will increasingly encounter patients using unregulated, unstudied products.
  • Safety remains uncertain due to lack of regulation, limited evidence, and potential harms from contamination, opioid effects, and withdrawal.
  • Physicians should assess kratom use, manage withdrawal and toxicity, and counsel patients about unknown risks and treatment options.
Summarise with AI (MRCPsych/FRANZCP)

Cleve Clin J Med. 2026 Aug 3;93(8):487-492. doi: 10.3949/ccjm.93a.25088.

ABSTRACT

As kratom products become more widely used in the United States, physicians will be more likely to encounter patients who are using these unregulated and unstudied substances. This focused review addresses questions such as what kratom is, whether it is safe, who is using it (and why), how to treat patients who are using it, and what to tell them.

PMID:42547284 | DOI:10.3949/ccjm.93a.25088

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

Save as PDF

My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD